EUROPEAN COOPERATION IN SCIENCE AND TECHNOLOGY

Minutes from the WG 3 Meeting

29. November 2013
8:00 a.m. – 12:00 a.m.
Madrid, Spain

A Selection of the most promising strategy to reach the goals set to WG3:
Following on the discussion and strategic decisions made in 1st our WG3 meeting the goals set during this initial meeting were again discussed extensively.

The conclusion from these discussions can be summarized as follows:

I The statements formulated in our 1st meeting and published in our minutes to this meeting were supported by the majority of the group:

a) Identification of the most challenging and urgent clinical research questions: From the biomarker stand point early detection (including Stage I PDAC and PanINs) as well as therapy response prediction in combination with an innovative targeted treatment initiatives based on omics data for PDAC (which should be discussed as a common goal for WG2 and 3) were identified as topics to put the main focus on (see also c and d).

b) Design a registry of candidate markers for pancreas cancer and Methodological review of current biomarker research in PDAC including review of current biomarker research in PDA (white paper): It was the opinion of the group that most currently published biomarker for PDAC are unimportant because they are unlikely to have an significant impact on improving mortality rates of PDAC. Therefore, it was decided not tie time and efforts of the group members to review mainly irrelevant biomarker data in order to prepare such a database.

II The strategy proposed for advancing early detection was seen very critical but nevertheless it was concluded that this effort should be continued as it was outlined in our minutes from the 1st meeting (minutes from 4/713, Bochum, 8c 1-2) but should include the experience from the London team (Steve Pereira), which is currently initiating a study on "Prospective evaluation of a novel early symptom algorithm and rapid assessment pathway for diagnosis of pancreatic cancer in primary care".

III It was agreed to set up a "COST" registry for already available biomaterial from early stage pancreatic cancer patients and tumors and to create a list of supporters for prospectively extending this virtual biomaterial bank.

IV Due to the problem IPMN pose in the clinical setting it was agreed to set up a COST initiated European IPMN study group. The tasks of this group will be:

- Set up a registry for already available sample
- Set up SOPS for patient workup and biomaterial collection
- Set up a list of contributors in a prospective collection for patients and samples
- Decide on the rules for use of biobank material

The goal should be to develop and test risk prediction biomarkers for IPMN

B Tasks to be completed before the end of March:

1.) Formation of a subgroup of WG3 members aiming at defining risk population criteria and put together a STSM proposal to reach this goal (see also minutes from 4/7/13 Bochum).

2.) Formation of a subgroup of WG3 members responsible to establish a "COST" registry for already available biomaterial from early stage pancreatic cancer.

Hemant

3.) Formation of a subgroup of WG3 members responsible to establish the COST European IPMN study group

Michalski (Leader)

C Next meeting

Two WG3 meetings to be held in 2014

Suggested Meeting time and place: 1st or 3rd Mai 2014 in London, prior or after the London Pancreas Workshop (2nd of May 2014). Doodle pool link: http://www.doodle.com/d2xepn4kc2f78uwy

Second meeting will be held late in 2014, location and date will be arranged among WG3 members

List of participants:

Paulina Gómez

Patrick Jacquemin

Ewout Steyerberg

Markus Lerch

Filipe Santos-Silva

Magdalena Majekova

Xavier Molero

Steve Pereira

Fieke Froeling

Bo Kong

Jörg Kleeff

Jens Siveke

Ewa Małecka-Panas

Ali CAGIR

Cristina Fillat

Julie Guillermet Guibert

Marlène Dufresne

Draienna Maqc (not sure this is spelled correct?)

Stephan Hahn